- GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF SJÖGREN'S SYNDROME ("SJS") AND SYSTEMIC LUPUS ERYTHEMATOSUS ("SLE")
- HANNOVER MEDICAL SCHOOL ("MHH") WILL COLLECT BIOSAMPLES FROM SJS AND SLE PATIENTS
- EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PATIENT STRATIFICATION AND CREATE NEW ENTRY POINTS FOR PRECISION MEDICINE DRUG DISCOVERY
HAMBURG, GERMANY / ACCESSWIRE / October 25, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced contiguous that the Company has entered a concern with Hannover Medical School ("MHH"), 1 of the starring German universities, to make a molecular diligent database for Sjögren's syndrome ("SjS") and systemic lupus erythematosus ("SLE").
The strategical concern betwixt Evotec and MHH aims astatine achieving a amended illness knowing of SjS and SLE by creating a unsocial longitudinal PanOmics database from the investigation of diligent material. Biospecimens from respective 100 SjS and SLE patients volition beryllium collected by MHH and analysed connected Evotec's PanOmics platform, which includes genomics, transcriptomics, proteomics, and metabolomics arsenic good arsenic single-cell sequencing technologies. Together with supplementary pseudonymised diligent data, these PanOmics information volition provender into Evotec's proprietary translational molecular diligent information level E.MPD, which serves arsenic the cardinal information repository for molecular diligent data.
For world research, MHH volition person entree to the information generated wrong the concern by moving with Evotec's AI-driven analytics bundle PanHunter. Evotec has the exclusive close to exploit the information commercially with its unsocial capabilities successful the tract of data-driven precision medicine. No fiscal presumption of the collaboration were disclosed.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to participate this concern with MHH and grow Evotec's E.MPD database into autoimmune diseases. The accepted symptomatic statement of galore diseases stands successful the mode of some diagnosis and effectual treatment. By leveraging PanOmics data, we are taking a deeper dive into underlying illness mechanisms. A amended knowing of molecular illness mechanisms guides the recognition of cardinal illness drivers and yet supports the recognition of caller targets and the improvement of effectual medicine."
Prof. Dr Torsten Witte, Professor of Rheumatology and Head of the Department of Rheumatology and Immunology astatine MHH, added: "So far, determination are nary efficacious anti-inflammatory therapies for Sjögren's syndrome and lone fewer for SLE. The recognition of inflammatory pathways contributing to the pathogenesis of the disorders would assistance to found caller therapies. Since these pathways whitethorn disagree interindividually, the probe task by MHH and Evotec whitethorn adjacent pave the roadworthy to individualised treatments of Sjögren's syndrome and SLE. We are truthful excited astir the possibilities of the collaboration that combines the expertise of the partners from MHH successful the nonstop objective characterisation of the patients and from Evotec successful the exertion of multi-omics technologies."
About Sjögren's syndrome and systemic lupus erythematosus
Sjögren's Syndrome ("SjS") and systemic lupus erythematosus ("SLE") are among the astir communal forms of rheumatic autoimmune diseases. However, the chartless triggers and symptoms betwixt patients makes aboriginal diagnosis of these conditions a challenging process, often spanning respective years - a question besides addressed by the RESIST cluster. Despite important probe enactment successful the field, not overmuch is known astir the causes and progression of either disease, truthful presently disposable attraction regimens are symptomatic and supportive.
About E.MPD
E.MPD, Evotec's translational molecular diligent database, is 1 of the largest and highest prime molecular databases globally. Evotec's integrated exertion platforms amusement that the champion mode to efficaciously dainty illness is to place underlying illness mechanisms and find the astir suitable therapy connected the ground of molecular information guiding each experimental processes towards aboriginal illness relevance. Therefore, information aggregation, integration, and the precise investigation of information is the captious way to effectual and affordable medicine successful the future.
E.MPD serves arsenic the backbone for data-driven partnerships that volition pb to innovative caller medicines, amended diligent stratification, and perchance pave the mode towards a caller paradigm of much effectual diagnostic and preventative healthcare. Through gathering and analysing patient-derived information successful operation with AI/ML tools, Evotec is besides capable to amended foretell some information and efficacy indicators successful cause development.
ABOUT EVOTEC SE
Evotec is simply a beingness subject institution with a unsocial concern exemplary that delivers connected its ngo to observe and make highly effectual therapeutics and marque them disposable to the patients. The Company's multimodality level comprises a unsocial operation of innovative technologies, information and subject for the discovery, development, and accumulation of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and wrong a web of partners including each Top 20 Pharma and implicit 800 biotechnology companies, world institutions, arsenic good arsenic different healthcare stakeholders. Evotec has strategical activities successful a wide scope of presently underserved therapeutic areas, including e.g. neurology, oncology, arsenic good arsenic metabolic and infectious diseases. Within these areas of expertise, Evotec aims to make the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of much than 200 proprietary and co-owned R&D projects from aboriginal find to objective development. Evotec operates globally with much than 4,500 highly qualified people. The Company's 16 sites connection highly synergistic technologies and services and run arsenic complementary clusters of excellence. For further accusation delight spell to www.evotec.com and travel america connected Twitter @Evotec and LinkedIn.
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning aboriginal events, including the projected offering and listing of Evotec's securities. Words specified arsenic "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of specified words and akin expressions are intended to place forward-looking statements. Such statements see comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based connected the accusation disposable to, and the expectations and assumptions deemed tenable by Evotec astatine the clip these statements were made. No assurance tin beryllium fixed that specified expectations volition beryllium to person been correct. These statements impact known and chartless risks and are based upon a fig of assumptions and estimates, which are inherently taxable to important uncertainties and contingencies, galore of which are beyond the power of Evotec. Evotec expressly disclaims immoderate obligations oregon undertaking to merchandise publically immoderate updates oregon revisions to immoderate forward-looking statements contained herein to bespeak immoderate alteration successful Evotec's expectations with respect thereto oregon immoderate alteration successful events, conditions oregon circumstances connected which immoderate connection is based.
Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications, Phone: +49.(0)40.56081-255, [email protected]
Hinnerk Rohwedder, Senior Specialist Corporate Communications, Tel.: +49.(0)151 4070-4843, [email protected]
IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, [email protected]
SOURCE: Evotec SE
English (US)